<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Ultrapure dialysis fluid
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Ultrapure dialysis fluid
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Ultrapure dialysis fluid
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nicholas Hoenich, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard A Ward, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey S Berns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dialysis fluid, produced by combining specially treated water with a concentrated electrolyte solution, is generally not sterile and may contain a range of microorganisms [
         <a href="#rid1">
          1-5
         </a>
         ] and bacterial products [
         <a href="#rid6">
          6-10
         </a>
         ]. Historically, some level of microbial contamination of the dialysis fluid was considered acceptable. This was based upon the false assumption that the dialyzer membrane provided an effective barrier against bacterial contamination of the blood during dialysis. However, subsequent studies demonstrated that bacterial products from the dialysis fluid were able to cross the dialyzer membrane [
         <a href="#rid11">
          11-13
         </a>
         ]. Such bacterial products were also capable of stimulating the immune system, possibly contributing to the heightened inflammatory state among patients receiving hemodialysis [
         <a href="#rid11">
          11-17
         </a>
         ]. Consequently, efforts to create a more stringent standard for the microbial quality of dialysis fluid led to the development of "ultrapure" dialysis fluid [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         The vast majority of conventional dialysis machines in the world are equipped to filter bacteria and endotoxins and, thereby, generate ultrapure dialysis fluid. However, regulatory agencies generally do not require dialysis units to comply with the standards for production of ultrapure fluid, except for fluid used to provide hemodiafiltration. (See
         <a class="medical medical_review" href="/z/d/html/94765.html" rel="external">
          "Technical aspects of hemodiafiltration", section on 'Components and technology of online HDF'
         </a>
         .)
        </p>
        <p>
         This topic will review the difference between ultrapure and standard dialysis fluid, the methods for production and monitoring of ultrapure dialysis fluid, and the clinical benefits of its use.
        </p>
        <p>
         Other aspects pertaining to dialysis fluid are covered elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A detailed discussion of contaminants and clinical manifestations of toxicity from such contaminants. (See
         <a class="medical medical_review" href="/z/d/html/1891.html" rel="external">
          "Contaminants in water used for hemodialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A detailed discussion of the water treatment system that produces standard dialysis fluid and monitoring of such a system. (See
         <a class="medical medical_review" href="/z/d/html/1896.html" rel="external">
          "Assuring water quality for hemodialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2662347322">
         <span class="h1">
          PRODUCTION OF ULTRAPURE DIALYSIS FLUID
         </span>
         <span class="headingEndMark">
          —
         </span>
         The difference between ultrapure and standard dialysis fluid is only based upon its microbiologic quality expressed in terms of maximum allowable levels for bacteria and endotoxins  (
         <a class="graphic graphic_table graphicRef131978" href="/z/d/graphic/131978.html" rel="external">
          table 1
         </a>
         ). The maximum allowable levels of chemical contaminants do not differ between ultrapure and standard dialysis fluid. The maximum allowable limits for various contaminants are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1891.html" rel="external">
          "Contaminants in water used for hemodialysis", section on 'Microbial contaminants'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1891.html" rel="external">
          "Contaminants in water used for hemodialysis", section on 'Clinically relevant contaminants'
         </a>
         .)
        </p>
        <p>
         Ultrapure dialysis fluid is produced by filtering standard dialysis fluid through one or more bacterial- and endotoxin-retentive ultrafilters immediately prior to the dialysis fluid entering the dialyzer (a process known as point-of-use ultrafiltration) [
         <a href="#rid19">
          19-22
         </a>
         ]. The production of standard dialysis fluid is discussed at length elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1896.html" rel="external">
          "Assuring water quality for hemodialysis"
         </a>
         .)
        </p>
        <p>
         Contemporary dialysis machines are designed with the bacterial- and endotoxin-retentive ultrafilters as integral components of the machine's dialysis fluid pathway [
         <a href="#rid23">
          23,24
         </a>
         ]. This design enables the ultrafilters to be disinfected whenever the dialysis machines are disinfected. Ultrafilters can also be retrofitted into some older dialysis machines. Ultrafilters should be used in accordance with the manufacturer's instructions for use [
         <a href="#rid23">
          23-26
         </a>
         ].
        </p>
        <p>
         Point-of-use ultrafiltration can reduce but not eliminate the level of bacterial endotoxin in the dialysis fluid. Some small bacterial products, such as fragments of bacterial DNA, are not filtered out [
         <a href="#rid6">
          6,27,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7081050">
         <span class="h1">
          ASSURING THE QUALITY OF ULTRAPURE DIALYSIS FLUID
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dialysis water can contain bacterial products from a variety of water-borne organisms, such as
         <em>
          Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Brevundimonas vesicularis, Alcaligenes
         </em>
         species,
         <em>
          Moraxella
         </em>
         ,
         <em>
          Corynebacterium
         </em>
         , fungi, and yeast [
         <a href="#rid1">
          1-5
         </a>
         ]. These organisms can enter from the incoming water supply, be housed within the water storage and distribution system, or be introduced when liquid, rather than powdered, bicarbonate concentrate is used for preparation of dialysis fluid. The microbiologic quality of ultrapure dialysis fluid is assured by maintaining a routine disinfection schedule of fluid pathways. In some cases, monitoring the quality of the ultrapure dialysis fluid is required.
        </p>
        <p class="headingAnchor" id="H997538644">
         <span class="h2">
          Maintenance of a routine disinfection schedule
         </span>
         <span class="headingEndMark">
          —
         </span>
         The routine disinfection process limits bacterial contamination and the formation of biofilm. The details regarding the schedule and process for routine disinfection are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1896.html" rel="external">
          "Assuring water quality for hemodialysis", section on 'Disinfection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3781204365">
         <span class="h2">
          Determining the need for quality assurance testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The routine quality assurance and monitoring of the ultrapure dialysis fluid produced by a conventional dialysis machine is
         <strong>
          not required
         </strong>
         if the dialysis machine and the ultrafilter are operated according to the manufacturer's instructions, specifically with regards to:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Replacement of the ultrafilter at the recommended interval (eg, the Diaclear filter should be replaced after use in 50 dialysis sessions or 100 heat disinfections)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         AND
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The dialysis water used to prepare the standard dialysis fluid, which then enters the ultrafilter, contains acceptable levels of bacteria (&lt;100 colony forming units [CFU]/mL) and endotoxin (&lt;0.25 endotoxin units [EU]/mL)
        </p>
        <p>
        </p>
        <p>
         Quality assurance of the ultrapure dialysis fluid should be performed if there is a deviation from any of the above conditions. Even in the absence of deviations, local regulatory bodies may require routine testing to ensure the quality of the ultrapure dialysis fluid. The process of quality assurance and monitoring is discussed below. (See
         <a class="local">
          'Process for quality assurance testing, if required'
         </a>
         below.)
        </p>
        <p>
         In addition to testing the product (ie, ultrapure dialysis fluid), some manufacturers may require routine testing of the dialysis water used for preparation of the dialysis fluid. The details regarding testing of the dialysis water are presented in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1896.html" rel="external">
          "Assuring water quality for hemodialysis", section on 'Sampling for microbiologic contaminants'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1896.html" rel="external">
          "Assuring water quality for hemodialysis", section on 'Testing for endotoxins'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2045702757">
         <span class="h2">
          Process for quality assurance testing, if required
         </span>
         <span class="headingEndMark">
          —
         </span>
         The monitoring of the microbiologic quality of the ultrapure dialysis fluid is performed by culture of the dialysis fluid produced and by direct measurement of endotoxin levels in that fluid.
        </p>
        <p class="headingAnchor" id="H102773266">
         <span class="h3">
          Culture
         </span>
         <span class="headingEndMark">
          —
         </span>
         Samples used for testing should be obtained before a disinfection cycle to capture bacterial growth at the highest possible levels. The samples should be drawn from a dialysis fluid sample port of the dialysis machine according to the machine manufacturer's instructions for use. The media that should be used for culture of ultrapure dialysis fluid are tryptone glucose extract agar (TGEA) or Reasoner's agar number 2 (R2A), both of which provide superior recovery of bacteria compared with other media such as tryptic soy agar (TSA) [
         <a href="#rid18">
          18,29-32
         </a>
         ]. Regardless of which medium is used, samples should be incubated at 17 to 23°C for seven days.
        </p>
        <p>
         Compared with sampling methods for standard dialysis fluid (pour plate or spread plate methods) (see
         <a class="medical medical_review" href="/z/d/html/1896.html" rel="external">
          "Assuring water quality for hemodialysis", section on 'Sampling for microbiologic contaminants'
         </a>
         ), those for ultrapure dialysis fluid need to have additional sensitivity. This is because, by design, fewer bacteria are present in ultrapure dialysis fluid compared with standard dialysis fluid. Instead, the sampling method suitable for ultrapure dialysis fluid is the membrane filtration method, which entails filtration of the dialysis fluid through a membrane filter with a pore diameter of ≤0.45 micrometer. The membrane filter (through which dialysis fluid has passed) is then applied directly to the surface of the incubation medium. The volume of fluid filtered should be sufficient to detect bacteria when they are present in that fluid at a concentration &lt;0.1 CFU/mL, the maximum allowable level for ultrapure dialysis fluid. This level of detection can be obtained by filtering 200 to 1000 mL. Historical data from prior testing of the dialysis fluid from the same source can be used as a guide to determine the amount of fluid to be filtered.
        </p>
        <p>
         In cases where historical data are unavailable, several membrane filters with different sample volumes filtered will need to be prepared for plating.
        </p>
        <p class="headingAnchor" id="H3692779988">
         <span class="h3">
          Measurement of endotoxin levels
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endotoxin levels are measured using the limulus amebocyte lysate (LAL) assay, a test based on the humoral coagulation cascade of the Atlantic horseshoe crab,
         <em>
          Limulus polyphemus
         </em>
         .
        </p>
        <p>
         There are three types of LAL assay: gel clot, turbidimetric, and chromogenic assay. The gel-clot assay, available in a range of sensitivities (0.015 to 0.5 EU/mL), is a semiquantitative assay that can be performed in a dialysis unit without the need for specialized laboratory equipment. While it is adequate for measurement of endotoxin levels in the ultrapure dialysis fluid, the gel-clot assay is the least sensitive of the three assays. The kinetic turbidimetric and kinetic chromogenic assays are both quantitative and capable of detecting much lower concentrations of endotoxin (as low as 0.001 EU/mL and 0.0002 EU/mL respectively). However, they both require specialized laboratory equipment and are generally not suited for use in a dialysis unit.
        </p>
        <p>
         The LAL cascade is activated by the binding of endotoxin to Factor C of the coagulation cascade. Factor C has been produced as a recombinant protein (rFC) and assays for endotoxin based on its binding to rFC are now available. In these assays, activated rFC cleaves a synthetic fluorogenic substrate causing the test solution to fluoresce. This approach provides a quantitative range of 0.005 to 5 EU/mL in a single step, with improved resolution compared with conventional kinetic LAL assays [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p>
         While these assays are sensitive for detection of endotoxin, they do not detect other proinflammatory bacterial products, such as oligonucleotides, peptidoglycans, or fragments of bacterial DNA [
         <a href="#rid6">
          6,27,28,35
         </a>
         ]. Other methods are available for detection of such substances but their use is not required as part of monitoring of ultrapure dialysis fluid [
         <a href="#rid6">
          6,7,28,35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12784512">
         <span class="h1">
          POTENTIAL CLINICAL BENEFITS OF ULTRAPURE DIALYSIS FLUID
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of ultrapure dialysis fluid is associated with a decline in the chronic inflammatory response that is common among hemodialysis patients [
         <a href="#rid6">
          6,14,36-51
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/1939.html" rel="external">
          "Inflammation in patients with kidney function impairment"
         </a>
         ); such a decline in inflammatory response may lower cardiovascular risk and provide other clinical benefits [
         <a href="#rid52">
          52-55
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unclear impact on mortality
         </strong>
         –
         <strong>
         </strong>
         In an observational study of over 130,000 patients receiving hemodialysis, compared with those exposed to dialysis fluid containing endotoxin levels of &lt;0.001 EU/mL (as in an ultrapure dialysate), patients exposed ≥0.1 EU/mL (as in a standard dialysate) had a 28 percent higher relative rate of all-cause mortality [
         <a href="#rid56">
          56
         </a>
         ]. However, in a trial of over 700 patients who were randomly assigned to receive either ultrapure or standard dialysate and either low-flux or high-flux dialysis (total of four groups), there was no meaningful difference in mortality between the two dialysate groups (24.7 versus 24.1 percent in ultrapure and standard dialysate groups, respectively) over a mean of 35 months [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Improvement in some surrogate endpoints
         </strong>
         – The use of ultrapure dialysis fluid is associated with improvement in the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rate of loss of residual kidney function (RKF)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anemia (decreased need for erythropoiesis-stimulating agents)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum albumin
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Inflammatory markers
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Markers of oxidative stress
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Beta-2 microglobulin
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Ultrapure dialysis fluid may slow the rate of decline in RKF. This was examined in one small trial of 30 patients who were randomly assigned to receive hemodialysis using either conventional or ultrapure dialysis fluid [
         <a href="#rid58">
          58
         </a>
         ]. At 24 months, compared with patients assigned to conventional dialysis fluid, those assigned to ultrapure dialysis fluid retained more RKF as defined by a higher measured 24-hour creatinine clearance (mean 4.3 versus 2.5 mL/min) and a higher 24-hour urine volume (mean 1 versus 0.5 L). In addition, patients treated with ultrapure dialysis fluid had lower C-reactive protein (CRP; mean 0.3 versus 0.8 mg/dL) and interleukin (IL)-6 (mean 11 versus 38 pg/mL).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In another study of 475 patients followed for two years, the rate of decline in RKF was comparable between patients who initiated on conventional hemodialysis with ultrapure dialysis fluid and those initiated on peritoneal dialysis [
         <a href="#rid59">
          59
         </a>
         ]. By contrast, prior studies have reported a faster rate of decline in RKF among patients receiving conventional hemodialysis compared with patients receiving peritoneal dialysis [
         <a href="#rid60">
          60-64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1941.html" rel="external">
          "Residual kidney function in kidney failure", section on 'Hemodialysis versus peritoneal dialysis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Changes in the remainder of the parameters were summarized in a meta-analysis of 31 studies (16 observational studies, 15 trials) and 1580 patients that compared outcomes among patients who converted to treatment with ultrapure dialysis fluid with those who remained on standard dialysis fluid [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the analysis of anemia parameters limited to trial data (206 patients), ultrapure dialysis fluid led to a small mean increase in hemoglobin (0.13 g/dL, 95% CI 0.0-0.26) and a decline in erythropoietin dose (-1188 units per week, 95% CI -2371 to -4), albeit with significant heterogeneity in the finding among included studies. No meaningful change was observed in serum transferrin saturation or ferritin levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the analysis of albumin limited to trial data (176 patients), compared with patients who remained on standard dialysis fluid, those converted to ultrapure dialysis fluid had a relative increase in serum albumin (mean 0.25 g/dL, 95% CI 0.02-0.48).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some inflammatory markers improved upon switching from standard to ultrapure dialysis fluid. As examples, CRP and IL-6 levels decreased. In the analysis limited to controlled trials (414 patients), the mean change in CRP was -4.4 mg/L (95% CI -7.5 to -1.3) and that in IL-6 was -11.6 pg/mL (95% CI -17.7 to -5.5). However, other markers such as tumor necrosis factor-alpha and IL-1 receptor antagonist remained without meaningful change.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There was also a decline in markers of oxidative stress such as pentosidine, myeloperoxidase, oxidized low-density lipoprotein, and beta-2 microglobulin.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Introduction to ultrapure dialysis fluid
         </strong>
         – Efforts to create a dialysis fluid meeting more stringent microbial quality standards led to the development of "ultrapure" dialysis fluid. The vast majority of dialysis units in the world that use conventional dialysis machines are capable of producing ultrapure dialysis fluid, but the production of such fluid is not always required by regulatory agencies. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Production
         </strong>
         – Ultrapure dialysis fluid is produced by filtering standard dialysis fluid through one or more bacterial- and endotoxin-retentive ultrafilters immediately before its entry into the dialyzer (a process known as point-of-use filtration). (See
         <a class="local">
          'Production of ultrapure dialysis fluid'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assuring quality
         </strong>
         – Unless mandated by local regulatory bodies, routine quality assurance testing of ultrapure dialysis fluid is not required if the ultrafilters are used according to the manufacturers' instructions for use. The quality assurance of ultrapure dialysis fluid, when required, is performed by culturing the fluid and by directly measuring the endotoxin levels in the fluid (see
         <a class="local">
          'Assuring the quality of ultrapure dialysis fluid'
         </a>
         above and
         <a class="local">
          'Determining the need for quality assurance testing'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Culture
         </strong>
         – Dialysis fluid should be sampled from the appropriate port on the dialysis machine before a disinfection cycle. For the assay to have sufficient sensitivity, the dialysis fluid needs to be filtered through a membrane filter with a pore diameter of ≤0.45 micrometer. The membrane filter is then plated on tryptone glucose extract agar or Reasoner's agar number 2 and incubated at 17 to 23°C for seven days. (See
         <a class="local">
          'Culture'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Measurement of endotoxin levels
         </strong>
         – The measurement of endotoxin levels should be performed using the limulus amebocyte lysate (LAL) assay. The gel-clot type of the LAL assay is generally adequate and can be used at the point-of-care. Additional, more sensitive methods are also available. (See
         <a class="local">
          'Measurement of endotoxin levels'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Potential clinical benefits
         </strong>
         – The use of ultrapure dialysis fluid may lead to a decline in the chronic inflammatory response that is common among hemodialysis patients; such a decline may lower cardiovascular risk and provide other clinical benefits such as improvement in anemia.
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Schiavano GF, Parlani L, Sisti M, et al. Occurrence of fungi in dialysis water and dialysate from eight haemodialysis units in central Italy. J Hosp Infect 2014; 86:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomila M, Gascó J, Busquets A, et al. Identification of culturable bacteria present in haemodialysis water and fluid. FEMS Microbiol Ecol 2005; 52:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arvanitidou M, Vayona A, Spanakis N, Tsakris A. Occurrence and antimicrobial resistance of Gram-negative bacteria isolated in haemodialysis water and dialysate of renal units: results of a Greek multicentre study. J Appl Microbiol 2003; 95:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma S, Indumathi VA, Gurudev KC, Naik SA. Bacteriological Quality of Treated Water and Dialysate in Haemodialysis Unit of A Tertiary Care Hospital. J Clin Diagn Res 2015; 9:DC14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damasiewicz MJ, Polkinghorne KR, Kerr PG. Water quality in conventional and home haemodialysis. Nat Rev Nephrol 2012; 8:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schindler R, Beck W, Deppisch R, et al. Short bacterial DNA fragments: detection in dialysate and induction of cytokines. J Am Soc Nephrol 2004; 15:3207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuchida K, Takemoto Y, Yamagami S, et al. Detection of peptidoglycan and endotoxin in dialysate, using silkworm larvae plasma and limulus amebocyte lysate methods. Nephron 1997; 75:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein E, Pass T, Harding GB, et al. Microbial and endotoxin contamination in water and dialysate in the central United States. Artif Organs 1990; 14:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Praditpornsilpa K, Tiranathanagul K, Susantitaphong P, et al. Effects of different levels of endotoxin contamination on inflammatory cytokine production by peripheral blood mononuclear cells after high-flux hemodialysis. Blood Purif 2011; 32:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glorieux G, Schepers E, Schindler R, et al. A novel bio-assay increases the detection yield of microbiological impurity of dialysis fluid, in comparison to the LAL-test. Nephrol Dial Transplant 2009; 24:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ureña P, Herbelin A, Zingraff J, et al. Permeability of cellulosic and non-cellulosic membranes to endotoxin subunits and cytokine production during in-vitro haemodialysis. Nephrol Dial Transplant 1992; 7:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schindler R, Christ-Kohlrausch F, Frei U, Shaldon S. Differences in the permeability of high-flux dialyzer membranes for bacterial pyrogens. Clin Nephrol 2003; 59:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lonnemann G, Behme TC, Lenzner B, et al. Permeability of dialyzer membranes to TNF alpha-inducing substances derived from water bacteria. Kidney Int 1992; 42:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lonnemann G. Chronic inflammation in hemodialysis: the role of contaminated dialysate. Blood Purif 2000; 18:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 2006; 11:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szeto CC, McIntyre CW, Li PK. Circulating Bacterial Fragments as Cardiovascular Risk Factors in CKD. J Am Soc Nephrol 2018; 29:1601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ledebo I, Nystrand R. Defining the microbiological quality of dialysis fluid. Artif Organs 1999; 23:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Section IV. Dialysis fluid purity. Nephrol Dial Transplant 2002; 17 Suppl 7:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward RA. Worldwide guidelines for the preparation and quality management of dialysis fluid and their implementation. Blood Purif 2009; 27 Suppl 1:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ledebo I. On-line preparation of solutions for dialysis: practical aspects versus safety and regulations. J Am Soc Nephrol 2002; 13 Suppl 1:S78.
          </a>
         </li>
         <li class="breakAll">
          International Organization for Standardization. Preparation and quality management of fluids for haemodialysis and related therapies – Part 5: Quality of dialysis fluid for haemodialysis and related therapies (ISO 23500-5:2019). Geneva, International Organization for Standardization, 2019.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lonnemann G, Mahiout A, Schindler R, Colton CK. Pyrogen retention by the polyamide membranes. Contrib Nephrol 1992; 96:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bommer J, Becker KP, Urbaschek R. Potential transfer of endotoxin across high-flux polysulfone membranes. J Am Soc Nephrol 1996; 7:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kashiwagi T, Sato K, Kawakami S, et al. The performance evaluation of endotoxin retentive filters in haemodialysis. J Nippon Med Sch 2011; 78:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glorieux G, Hulko M, Speidel R, et al. Looking beyond endotoxin: a comparative study of pyrogen retention by ultrafilters used for the preparation of sterile dialyis fluid. Sci Rep 2014; 4:6390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tao X, Hoenich N, Handelman SK, et al. Transfer of low-molecular weight single-stranded DNA through the membrane of a high-flux dialyzer. Int J Artif Organs 2014; 37:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bossola M, Sanguinetti M, Scribano D, et al. Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Linde K, Lim BT, Rondeel JM, et al. Improved bacteriological surveillance of haemodialysis fluids: a comparison between Tryptic soy agar and Reasoner's 2A media. Nephrol Dial Transplant 1999; 14:2433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harding GB, Pass T, Million C, et al. Bacterial contamination of hemodialysis center water and dialysate: are current assays adequate? Artif Organs 1989; 13:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pass T, Wright R, Sharp B, Harding GB. Culture of dialysis fluids on nutrient-rich media for short periods at elevated temperatures underestimate microbial contamination. Blood Purif 1996; 14:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maltais JB, Meyer KB, Foster MC. Comparison of techniques for culture of dialysis water and fluid. Hemodial Int 2017; 21:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tindall B, Demircioglu D, Uhlig T. Recombinant bacterial endotoxin testing: a proven solution. Biotechniques 2021; 70:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piehler M, Roeder R, Blessing S, Reich J. Comparison of LAL and rFC Assays-Participation in a Proficiency Test Program between 2014 and 2019. Microorganisms 2020; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glorieux G, Neirynck N, Veys N, Vanholder R. Dialysis water and fluid purity: more than endotoxin. Nephrol Dial Transplant 2012; 27:4010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pecoits-Filho R, Heimbürger O, Bárány P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41:1212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodial Int 2004; 8:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lonnemann G. When good water goes bad: how it happens, clinical consequences and possible solutions. Blood Purif 2004; 22:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffl H, Lang SM, Stratakis D, Fischer R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant 2001; 16:1863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuhashi N, Yoshioka T. Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients. Nephron 2002; 92:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arizono K, Nomura K, Motoyama T, et al. Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purif 2004; 22 Suppl 2:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu PY, Lin CL, Yu CC, et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study. J Nephrol 2004; 17:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furuya R, Kumagai H, Takahashi M, et al. Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients. Blood Purif 2005; 23:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molina M, Navarro MJ, Palacios ME, et al. [Importance of ultrapure dialysis liquid in response to the treatment of renal anaemia with darbepoetin in patients receiving haemodialysis]. Nefrologia 2007; 27:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Go I, Takemoto Y, Tsuchida K, et al. The effect of ultrapure dialysate on improving renal anemia. Osaka City Med J 2007; 53:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Susantitaphong P, Riella C, Jaber BL. Effect of ultrapure dialysate on markers of inflammation, oxidative stress, nutrition and anemia parameters: a meta-analysis. Nephrol Dial Transplant 2013; 28:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Handelman GJ, Megdal PA, Handelman SK. Bacterial DNA in water and dialysate: detection and significance for patient outcomes. Blood Purif 2009; 27:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Iorio B, Di Micco L, Bruzzese D, et al. Ultrapure dialysis water obtained with additional ultrafilter may reduce inflammation in patients on hemodialysis. J Nephrol 2017; 30:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honda H, Qureshi AR, Heimbürger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herbelin A, Ureña P, Nguyen AT, et al. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991; 39:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang W, He J, Zhang F, et al. Prognostic role of C-reactive protein and interleukin-6 in dialysis patients: a systematic review and meta-analysis. J Nephrol 2013; 26:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasegawa T, Nakai S, Masakane I, et al. Dialysis fluid endotoxin level and mortality in maintenance hemodialysis: a nationwide cohort study. Am J Kidney Dis 2015; 65:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asci G, Tz H, Ozkahya M, et al. The impact of membrane permeability and dialysate purity on cardiovascular outcomes. J Am Soc Nephrol 2013; 24:1014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2002; 17:1814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKane W, Chandna SM, Tattersall JE, et al. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int 2002; 61:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rottembourg J. Residual renal function and recovery of renal function in patients treated by CAPD. Kidney Int Suppl 1993; 40:S106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lysaght MJ, Vonesh EF, Gotch F, et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 1991; 37:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Misra M, Vonesh E, Van Stone JC, et al. Effect of cause and time of dropout on the residual GFR: a comparative analysis of the decline of GFR on dialysis. Kidney Int 2001; 59:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jansen MA, Hart AA, Korevaar JC, et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62:1046.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1948 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24556142" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Occurrence of fungi in dialysis water and dialysate from eight haemodialysis units in central Italy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16329897" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Identification of culturable bacteria present in haemodialysis water and fluid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12807469" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Occurrence and antimicrobial resistance of Gram-negative bacteria isolated in haemodialysis water and dialysate of renal units: results of a Greek multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26557519" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Bacteriological Quality of Treated Water and Dialysate in Haemodialysis Unit of A Tertiary Care Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23090444" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Water quality in conventional and home haemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15579524" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Short bacterial DNA fragments: detection in dialysate and induction of cytokines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9127331" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Detection of peptidoglycan and endotoxin in dialysate, using silkworm larvae plasma and limulus amebocyte lysate methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2350260" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Microbial and endotoxin contamination in water and dialysate in the central United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21447946" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Effects of different levels of endotoxin contamination on inflammatory cytokine production by peripheral blood mononuclear cells after high-flux hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18768583" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A novel bio-assay increases the detection yield of microbiological impurity of dialysis fluid, in comparison to the LAL-test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1316577" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Permeability of cellulosic and non-cellulosic membranes to endotoxin subunits and cytokine production during in-vitro haemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12834177" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Differences in the permeability of high-flux dialyzer membranes for bacterial pyrogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1635355" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Permeability of dialyzer membranes to TNF alpha-inducing substances derived from water bacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10859424" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Chronic inflammation in hemodialysis: the role of contaminated dialysate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9987089" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16509930" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Inflammation in end-stage renal disease: the hidden enemy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29666156" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Circulating Bacterial Fragments as Cardiovascular Risk Factors in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9950177" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Defining the microbiological quality of dialysis fluid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12386221" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Section IV. Dialysis fluid purity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19556755" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Worldwide guidelines for the preparation and quality management of dialysis fluid and their implementation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11792766" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : On-line preparation of solutions for dialysis: practical aspects versus safety and regulations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11792766" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : On-line preparation of solutions for dialysis: practical aspects versus safety and regulations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1740050" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Pyrogen retention by the polyamide membranes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8793797" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Potential transfer of endotoxin across high-flux polysulfone membranes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21869555" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The performance evaluation of endotoxin retentive filters in haemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25227511" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Looking beyond endotoxin: a comparative study of pyrogen retention by ultrafilters used for the preparation of sterile dialyis fluid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25044384" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Transfer of low-molecular weight single-stranded DNA through the membrane of a high-flux dialyzer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19118119" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10528669" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Improved bacteriological surveillance of haemodialysis fluids: a comparison between Tryptic soy agar and Reasoner's 2A media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2650659" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Bacterial contamination of hemodialysis center water and dialysate: are current assays adequate?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8785029" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Culture of dialysis fluids on nutrient-rich media for short periods at elevated temperatures underestimate microbial contamination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27594052" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Comparison of techniques for culture of dialysis water and fluid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33956506" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Recombinant bacterial endotoxin testing: a proven solution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32188126" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Comparison of LAL and rFC Assays-Participation in a Proficiency Test Program between 2014 and 2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22844107" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Dialysis water and fluid purity: more than endotoxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12358637" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Inflammation in end-stage renal disease: sources, consequences, and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12776273" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Associations between circulating inflammatory markers and residual renal function in CRF patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14871421" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19379407" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14732820" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : When good water goes bad: how it happens, clinical consequences and possible solutions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10910446" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11522871" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12372943" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15655319" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15593037" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15980621" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17564565" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : [Importance of ultrapure dialysis liquid in response to the treatment of renal anaemia with darbepoetin in patients receiving haemodialysis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17867630" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The effect of ultrapure dialysate on improving renal anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23291370" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effect of ultrapure dialysate on markers of inflammation, oxidative stress, nutrition and anemia parameters: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19169023" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Bacterial DNA in water and dialysate: detection and significance for patient outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28840494" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Ultrapure dialysis water obtained with additional ultrafilter may reduce inflammation in patients on hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9690231" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : C-reactive protein as an outcome predictor for maintenance hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16377395" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2067212" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Elevated circulating levels of interleukin-6 in patients with chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22684644" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Prognostic role of C-reactive protein and interleukin-6 in dialysis patients: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25641063" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Dialysis fluid endotoxin level and mortality in maintenance hemodialysis: a nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23620396" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The impact of membrane permeability and dialysate purity on cardiovascular outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12270990" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11786108" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8445831" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Residual renal function and recovery of renal function in patients treated by CAPD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1768496" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The influence of dialysis treatment modality on the decline of remaining renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10703680" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Predictors of loss of residual renal function among new dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11168959" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Effect of cause and time of dropout on the residual GFR: a comparative analysis of the decline of GFR on dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12164889" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Predictors of the rate of decline of residual renal function in incident dialysis patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
